OncoCyte secured $5.74 million after certain warrant holders exercised around 1.77 million common stock purchase warrants. The proceeds will be used to develop the company's liquid biopsy diagnostics for breast and lung cancer as well as to prepare for this year's release of its lung cancer diagnostic, said company President and CEO William Annet.
Exercise of warrants brings in $5.74M for OncoCyte
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.